{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:13Z","timestamp":1791357493794,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jad-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jad.2013.02.003","type":"journal-article","created":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T11:01:08Z","timestamp":1363604468000},"page":"319-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study"],"prefix":"10.1016","volume":"149","author":[{"given":"Jose A.","family":"Franco-Chaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo F.","family":"Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Luckenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro E.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Mallinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2013.02.003_bib1","unstructured":"American Psychiatric Association, 2010. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. American Psychiatric Association, Arlington, VA."},{"key":"10.1016\/j.jad.2013.02.003_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","article-title":"Role of pramipexole in the management of Parkinson\u2019s disease","volume":"24","author":"Antonini","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2013.02.003_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5665\/sleep.1986","article-title":"The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an american academy of sleep medicine clinical practice guideline","volume":"35","author":"Aurora","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.jad.2013.02.003_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/da.20080","article-title":"Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study","volume":"22","author":"Baldomero","year":"2005","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.jad.2013.02.003_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/01.yic.0000194377.88330.1d","article-title":"A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder","volume":"21","author":"Baldwin","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.jad.2013.02.003_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study","volume":"253","author":"Barone","year":"2006","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.jad.2013.02.003_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nature Review Neuroscience"},{"key":"10.1016\/j.jad.2013.02.003_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/da.20038","article-title":"Pramipexole in treatment-resistant depression: an extended follow-up","volume":"20","author":"Cassano","year":"2004","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.jad.2013.02.003_bib9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1471-4159.1998.71010295.x","article-title":"Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion","volume":"71","author":"Cassarino","year":"1998","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.jad.2013.02.003_bib10","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1046\/j.1471-4159.2000.0741384.x","article-title":"Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease","volume":"74","author":"Cassarino","year":"2000","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.jad.2013.02.003_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.jad.2013.02.003_bib12","unstructured":"First, M.B., Spitzer, R.L., Gibbon, M., Williams, A.R., 2001. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/P). New York State Psychiatric Institute, Biometrics Research, New York."},{"key":"10.1016\/j.jad.2013.02.003_bib13","unstructured":"Forest Laboratories, I., 2011. Lexapro Prescribing Information."},{"key":"10.1016\/j.jad.2013.02.003_bib14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-149-10-200811180-00008","article-title":"Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians","volume":"149","author":"Gartlehner","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jad.2013.02.003_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.7326\/0003-4819-155-11-201112060-00009","article-title":"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis","volume":"155","author":"Gartlehner","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jad.2013.02.003_bib16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00702-003-0027-5","article-title":"Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum","volume":"110","author":"Gerlach","year":"2003","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.jad.2013.02.003_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","article-title":"Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression","volume":"161","author":"Goldberg","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1017\/S1092852900028595","article-title":"Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials","volume":"7","author":"Gorman","year":"2002","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.jad.2013.02.003_bib19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2174\/138945009789735156","article-title":"Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors","volume":"10","author":"Guiard","year":"2009","journal-title":"Currents Drug Targets"},{"key":"10.1016\/j.jad.2013.02.003_bib20","first-page":"21","article-title":"Rating depressive patients","volume":"41","author":"Hamilton","year":"1980","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib21","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.pnpbp.2010.07.035","article-title":"Pramipexole for stage 2 treatment-resistant major depression: an open study","volume":"34","author":"Inoue","year":"2010","journal-title":"Progress in NeuroPsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib22","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1001\/jama.289.23.3167","article-title":"Research on major depression: strategies and priorities","volume":"289","author":"Insel","year":"2003","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jad.2013.02.003_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000056257","article-title":"Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts general hospital sexual functioning questionnaire","volume":"70","author":"Labbate","year":"2001","journal-title":"Psychotheraphy and Psychosomatics"},{"key":"10.1016\/j.jad.2013.02.003_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1399-5618.2002.01171.x","article-title":"Pramipexole in treatment-resistant depression: a 16-week naturalistic study","volume":"4","author":"Lattanzi","year":"2002","journal-title":"Bipolar Disorder"},{"key":"10.1016\/j.jad.2013.02.003_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002512-200118060-00001","article-title":"Are dopamine receptor agonists neuroprotective in Parkinson's disease?","volume":"18","author":"Le","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jad.2013.02.003_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/YIC.0b013e3282f424c2","article-title":"Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor","volume":"23","author":"Lenox-Smith","year":"2008","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.jad.2013.02.003_bib27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial","volume":"20","author":"Moller","year":"2005","journal-title":"Movement Disorders"},{"key":"10.1016\/j.jad.2013.02.003_bib28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000078225","article-title":"A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder","volume":"50","author":"Montgomery","year":"2004","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2013.02.003_bib30","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2165\/00003495-200565160-00013","article-title":"Escitalopram: a review of its use in the management of major depressive disorder","volume":"65","author":"Murdoch","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2013.02.003_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2007.06.027","article-title":"Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs","volume":"63","author":"Nemeroff","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","article-title":"Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study","volume":"23","author":"Nierenberg","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.jad.2013.02.003_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","article-title":"Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"50","author":"Owens","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.biopsych.2007.03.027","article-title":"Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents","volume":"62","author":"Papakostas","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2001-15872","article-title":"Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series","volume":"34","author":"Perugi","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1192\/bjp.175.1.12","article-title":"Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison","volume":"175","author":"Poirier","year":"1999","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study","volume":"10","author":"Rektorova","year":"2003","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.jad.2013.02.003_bib38","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jad.2013.02.003_bib39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.eurpsy.2009.07.012","article-title":"Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database","volume":"25","author":"Serna","year":"2010","journal-title":"European Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10401230009147102","article-title":"Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review","volume":"12","author":"Sporn","year":"2000","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(00)02493-8","article-title":"Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole","volume":"872","author":"Takata","year":"2000","journal-title":"Brain Research"},{"key":"10.1016\/j.jad.2013.02.003_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u204eD: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jad.2013.02.003_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0079-6123(08)00913-8","article-title":"Dynamics of the dopaminergic system as a key component to the understanding of depression","volume":"172","author":"Yadid","year":"2008","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.jad.2013.02.003_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopsych.2004.03.013","article-title":"Pramipexole for bipolar II depression: a placebo-controlled proof of concept study","volume":"56","author":"Zarate","year":"2004","journal-title":"Biological Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032713001183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032713001183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T23:54:46Z","timestamp":1539820486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032713001183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":44,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0165032713001183"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2013.02.003","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2013.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}